SOAT1 and acute myeloid leukemia: For example, combining ruxolitinib (a JAK2 inhibitor) with BCL-2 inhibitors, such as venetoclax, has shown promising results in treating AML and ALL by targeting both the anti-apoptotic mechanisms and JAK-STAT pathway.